New chikungunya vaccine shows promise in early trial

NCT ID NCT06669208

Completed ⭐️ VACCINE ⭐️ Sponsor: Najit Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an inactivated chikungunya virus vaccine called HydroVax-005 CHIKV in 48 healthy adults aged 18 to 49. Participants received two doses of either a low or high dose of the vaccine or a placebo. The main goal was to check safety and how well the vaccine triggers an immune response. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HydroVax-005 CHIKV vaccine (inactivated chikungunya virus)
What this could lead to: If successful, this could lead to a safe and effective vaccine to prevent chikungunya fever, a painful mosquito-borne disease.
What could go wrong: This is an early Phase 1 trial with only 48 participants, so results may not apply to larger populations. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA CHIKUNGUNYA FEVER CHIKUNGUNYA VIRUS

Contacts and locations

Locations

Duke University Health System

Durham, North Carolina, 27705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.